Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 11, 2026 · Other material event · Item 3.02 · Financial statements
Xeris Biopharma Holdings, Inc.
9
Other material event
Jun 11, 2026
| Item 3.02 | Item 3.02 |
| Item 8.01 | Other events the company considers material |
| Item 9.01 | Financial statements and exhibits |
Xeris Biopharma Holdings, Inc. filed this to release information to investors under Regulation FD, usually a press release, conference presentation, or other event the company considers important. 1 XERIS BIOPHARMA ANNOUNCES PRIVATE EXCHANGE OF CONVERTIBLE NOTES Eliminates approximately $23 million of debt, resulting in approximately $2 million in annual interest savings Principal to be paid in cash, remainder in common stock CHICAGO, IL; June 11, 2026 – Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed…
This filing reports Item 8.01 (other events the company considers material). These item codes often precede or accompany restructuring, leadership changes, or deals that can shift headcount.
Xeris Biopharma Holdings, Inc. reported material events that can affect workforce planning. cutoffs surfaces the filing alongside WARN layoffs, H-1B activity, and company signals.
